{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:09:38Z","timestamp":1791882578290,"version":"4.3.4"},"reference-count":25,"publisher":"Becaris Publishing Limited","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Time to treatment and pretreatment costs may be affected by unknown primary tumor site.\n            <jats:bold>Methods:<\/jats:bold>\n            This retrospective study used electronic medical record data from patients in ten US community oncology practices. Eligible patients were \u226518\u00a0years, diagnosed with cancer of unknown primary (CUP) or known metastatic solid tumor, and presented between 1 January 2012 and 30\u00a0June 2014.\n            <jats:bold>Results:<\/jats:bold>\n            Patients with CUP (n\u00a0=\u00a0294) had a longer interval than non-CUP patients (n\u00a0=\u00a092) from presentation to treatment initiation (1.18 vs 0.49\u00a0months, p\u00a0&lt;\u00a00.0001), and had higher pretreatment costs (US$27,882 vs US$20,449, p\u00a0=\u00a00.0075). When analyzed as monthly cost, the difference between groups in log-cost per month was nonsignificant.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Higher pretreatment costs in CUP patients appeared attributable to significantly longer time to initiation of therapy.\n          <\/jats:p>","DOI":"10.2217\/cer-2017-0104","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T10:11:16Z","timestamp":1527847876000},"page":"523-533","source":"Crossref","is-referenced-by-count":7,"title":["Pretreatment costs of care and time to initial treatment for patients with cancer of unknown primary"],"prefix":"10.57264","volume":"7","author":[{"given":"Mark S","family":"Walker","sequence":"first","affiliation":[{"name":"Vector Oncology, Memphis, TN 38119, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, MA 02141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Luo","sequence":"additional","affiliation":[{"name":"Vector Oncology, Memphis, TN 38119, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Marino","sequence":"additional","affiliation":[{"name":"Foundation Medicine Inc., Cambridge, MA 02141, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"9824","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis N","year":"2012","unstructured":"Pavlidis N , Pentheroudakis G . Cancer of unknown primary site . Lancet 379 ( 9824 ), 1428 \u2013 1435 ( 2012 ).","journal-title":"Lancet"},{"issue":"21","key":"e_1_3_5_4_2","first-page":"2040","article-title":"Carcinoma of unknown primary site","volume":"371","author":"Varadhachary GR","year":"2014","unstructured":"Varadhachary GR , Raber MN . Carcinoma of unknown primary site . N. Engl. J. Med. 371 ( 21 ), 2040 ( 2014 ).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/annonc\/mds357","article-title":"Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling","volume":"23","author":"Oien K","year":"2012","unstructured":"Oien K , Dennise JL . Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling . Ann. Oncol. 23 ( Suppl. 10 ), 271 \u2013 277 ( 2012 ).","journal-title":"Ann. Oncol."},{"issue":"12","key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrclinonc.2011.158","article-title":"Carcinomas of an unknown primary origin \u2013 diagnosis and treatment","volume":"8","author":"Massard C","year":"2011","unstructured":"Massard C , Loriot Y , Fizazi K . Carcinomas of an unknown primary origin \u2013 diagnosis and treatment . Nat. Rev. Clin. Oncol. 8 ( 12 ), 701 \u2013 710 ( 2011 ).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1002\/ijc.28874","article-title":"Risk factors for cancers of unknown primary site: results from the prospective EPIC cohort","volume":"135","author":"Kaaks R","year":"2014","unstructured":"Kaaks R , Sookthai D , Hemminki K Risk factors for cancers of unknown primary site: results from the prospective EPIC cohort . Int. J. Cancer 135 ( 10 ), 2475 \u2013 2481 ( 2014 ).","journal-title":"Int. J. Cancer"},{"issue":"3","key":"e_1_3_5_8_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.critrevonc.2008.09.005","article-title":"Carcinoma of unknown primary (CUP)","volume":"69","author":"Pavlidis N","year":"2009","unstructured":"Pavlidis N , Fizazi K . Carcinoma of unknown primary (CUP) . Crit. Rev. Oncol. Hematol. 69 ( 3 ), 271 \u2013 278 ( 2009 ).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10552-014-0378-2","article-title":"Cancer of unknown primary: time trends in incidence, United States","volume":"25","author":"Mnatsakanyan E","year":"2014","unstructured":"Mnatsakanyan E , Tung WC , Caine B , Smith-Gagen J . Cancer of unknown primary: time trends in incidence, United States . Cancer Causes Control 25 ( 6 ), 747 \u2013 757 ( 2014 ).","journal-title":"Cancer Causes Control"},{"issue":"1","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume":"1","author":"Ross JS","year":"2015","unstructured":"Ross JS , Wang K , Gay L Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies . JAMA Oncol. 1 ( 1 ), 40 \u2013 49 ( 2015 ).","journal-title":"JAMA Oncol."},{"key":"e_1_3_5_11_2","unstructured":"American Cancer Society\n                        . \n                        Cancer Facts & Figures 2016\n                        . (\n                        2016\n                        ). \n                        www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2016\/cancer-facts-and-figures-2016.pdf"},{"issue":"2","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/annonc\/mdr306","article-title":"Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes","volume":"23","author":"Greco FA","year":"2012","unstructured":"Greco FA , Oien K , Erlander M Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes . Ann. Oncol. 23 ( 2 ), 298 \u2013 304 ( 2012 ).","journal-title":"Ann. Oncol."},{"issue":"5","key":"e_1_3_5_13_2","first-page":"659","article-title":"Incidence, costs of care and mortality of medicare beneficiaries diagnosed with cancer of unknown primary (CUP)","volume":"8","author":"Tong KB","year":"2006","unstructured":"Tong KB , Becker SH , Anderson GG . Incidence, costs of care and mortality of medicare beneficiaries diagnosed with cancer of unknown primary (CUP) . JMD 8 ( 5 ), 659 ( 2006 ).","journal-title":"JMD"},{"issue":"5","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi K","year":"2015","unstructured":"Fizazi K , Greco FA , Pavlidis N , Daugaard G , Oien K , Pentheroudakis G . Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up . Ann. Oncol. 26 ( Suppl. 5 ), v133 \u2013 v138 ( 2015 ).","journal-title":"Ann. Oncol."},{"issue":"11","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clon.2013.06.008","article-title":"Cancer of unknown primary presenting with liver metastasis: a cost, time to treatment and outcome analysis","volume":"25","author":"Saif Ur Rehman S","year":"2013","unstructured":"Saif Ur Rehman S , Ahluwalia MS , Mashtare TL Cancer of unknown primary presenting with liver metastasis: a cost, time to treatment and outcome analysis . Clin. Oncol. 25 ( 11 ), 684 \u2013 685 ( 2013 ).","journal-title":"Clin. Oncol."},{"issue":"3","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1634\/theoncologist.2-3-142","article-title":"Cancer of unknown primary origin","volume":"2","author":"Briasoulis E","year":"1997","unstructured":"Briasoulis E , Pavlidis N . Cancer of unknown primary origin . Oncologist 2 ( 3 ), 142 \u2013 152 ( 1997 ).","journal-title":"Oncologist"},{"key":"e_1_3_5_17_2","unstructured":"Barrett\n                                M Steiner\n                                C Sheng\n                                M Bailey\n                                M\n                        . \n                        Healthcare Cost and Utilization Project HCUP) External Cause of Injury Code (E Code) Evaluation Report (Updated with 2013 HCUP Data). 2016. HCUP Methods Series Report # 2016\u201303 ONLINE\n                        . \n                        July 26 2016\n                        . \n                        U.S. Agency for Healthcare Research and Quality\n                        . \n                        www.hcup-us.ahrq.gov\/reports\/methods\/methods.jsp"},{"key":"e_1_3_5_18_2","unstructured":"United States Centers for Medicare & Medicaid Services (CMS)\n                        . \n                        Physician Fee Schedule\n                        . \n                        2016 July 26\n                         (\n                        2014\n                        ). \n                        www.cms.gov\/medicare\/medicare-fee-for-service-payment\/physicianfeesched\/index.html"},{"key":"e_1_3_5_19_2","unstructured":"Truven Health Analytics\n                        . \n                        RED BOOK from Micromedex Solutions\n                        . \n                        2016 July 26\n                         (\n                        2015\n                        ). \n                        http:\/\/micromedex.com\/redbook"},{"key":"e_1_3_5_20_2","article-title":"The potential clinical and economic value of primary tumour identification in metastatic cancer of unknown primary tumour: a population-based retrospective matched cohort study","author":"Hannouf MB","year":"2017","unstructured":"Hannouf MB , Winquist E , Mahmud SM The potential clinical and economic value of primary tumour identification in metastatic cancer of unknown primary tumour: a population-based retrospective matched cohort study . Pharmacoecon Open doi:10.1007\/s41669-017-0051-2 ( 2017 ) ( Epub ahead of print ).","journal-title":"Pharmacoecon Open"},{"key":"e_1_3_5_21_2","unstructured":"Soni\n                                A\n                        . \n                        Trends in use and expenditures for cancer treatment among adults 18 and older U.S. civilian noninstitutionalized population 2001 and 2011\n                        . \n                        Statistical Brief #443\n                         (\n                        2014\n                        ). \n                        https:\/\/meps.ahrq.gov\/data_files\/publications\/st443\/stat443.pdf"},{"issue":"32","key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","article-title":"Impact of precision medicine in diverse cancers: a meta-analysis of Phase II clinical trials","volume":"33","author":"Schwaederle M","year":"2015","unstructured":"Schwaederle M , Zhao M , Lee JJ Impact of precision medicine in diverse cancers: a meta-analysis of Phase II clinical trials . J. Clin. Oncol. 33 ( 32 ), 3817 \u2013 3825 ( 2015 ).","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1158\/0008-5472.CAN-15-3043","article-title":"Cancer therapy directed by comprehensive genomic profiling: a single center study","volume":"76","author":"Wheler JJ","year":"2016","unstructured":"Wheler JJ , Janku F , Naing A Cancer therapy directed by comprehensive genomic profiling: a single center study . Cancer Res. 76 ( 13 ), 3690 \u2013 3701 ( 2016 ).","journal-title":"Cancer Res."},{"issue":"3","key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/tpj.2015.94","article-title":"Cost\u2013effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary","volume":"17","author":"Hannouf MB","year":"2017","unstructured":"Hannouf MB , Winquist E , Mahmud SM Cost\u2013effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary . Pharmacogenomics J. 17 ( 3 ), 286 \u2013 300 ( 2017 ).","journal-title":"Pharmacogenomics J."},{"issue":"4","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/bmjspcare-2013-000482","article-title":"Uncertainty and anxiety in the cancer of unknown primary patient journey: a multiperspective qualitative study","volume":"5","author":"Richardson A","year":"2015","unstructured":"Richardson A , Wagland R , Foster R Uncertainty and anxiety in the cancer of unknown primary patient journey: a multiperspective qualitative study . BMJ Support Palliat. Care 5 ( 4 ), 366 \u2013 372 ( 2015 ).","journal-title":"BMJ Support Palliat. Care"},{"issue":"7","key":"e_1_3_5_26_2","first-page":"A356","article-title":"Economic analysis of epicup, an epigenetic test to predict the tissue of origin in cancer of unknown primary site, the USA payors perspective","volume":"18","author":"Gracia A","year":"2015","unstructured":"Gracia A , Balana C , Kaskens L Economic analysis of epicup, an epigenetic test to predict the tissue of origin in cancer of unknown primary site, the USA payors perspective . Value Health 18 ( 7 ), A356 ( 2015 ).","journal-title":"Value Health"},{"issue":"12","key":"e_1_3_5_27_2","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/hed.23830","article-title":"Cost-effectiveness of positron emission tomography-CT in the evaluation of cancer of unknown primary of the head and neck","volume":"37","author":"Smith KA","year":"2015","unstructured":"Smith KA , Dort JC , Hall SF , Rudmik L . Cost-effectiveness of positron emission tomography-CT in the evaluation of cancer of unknown primary of the head and neck . Head Neck 37 ( 12 ), 1781 \u2013 1787 ( 2015 ).","journal-title":"Head Neck"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2017-0104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:28:26Z","timestamp":1679228906000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2017-0104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.2217\/cer-2017-0104"],"URL":"https:\/\/doi.org\/10.2217\/cer-2017-0104","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}